Development of immunotherapeutic tools for cancer treatment
One Special Engineer position is available for 5 months, from February 1st 2024, at the Department of Cellular Therapy (Dr. Sébastien Wälchli) and at the Institute for Cancer Research (Dr. Jorrit Enserink), Oslo University Hospital (OUS) Radiumhospitalet.

The organization and focus of the research groups
The focus of the Wälchli group is to develop new immunotherapy treatments against cancer. This includes the pre-clinical and clinical development and testing of enhanced cancer vaccines, adoptive T-cell therapy (TCR, CAR) and the improvement of cellular therapy for increased resistance to the microenvironment. The group is located at the Oslo Cancer Cluster Incubator (occincubator.com) and interacts actively with industries and pharmaceutical companies.
The Enserink group is located at the Radium hospital, which is part of Oslo University Hospital, the largest academic hospital in Scandinavia. The group is a member of a Norwegian Centre of Excellence (Centre for Cancer Cell Reprogramming, CanCell), which consists of six research groups focused on finding novel mechanisms in cancer development that can be targeted with novel cancer therapy. One of the main research aims of the group is to better understand the biology of cancer and use this knowledge to develop anticancer therapies.

 

Oslo University Hospital is a workplace with great diversity. We believe this is essential to perform the tasks required of us. Therefore, we pursue diversity among our job applicants and encourage everyone to apply regardless of who you are and what background you have.

Kvalifikasjoner:

Due to the short period for completing these experiments, the candidate needs a very specific skillset related to CAR studies. Therefore, only experienced scientists who can document previous experiment with all the following methods will be considered:
Primary T cell manipulation (expansion, retroviral transduction).
CAR expression and testing: killing assay (BLI), cytokine release assay (Bioplex), Live cell imaging (IncuCyte), metabolic studies (Seahorse), affinity study (z-movi)
In vivo: the candidate must hold a FELASA-C or equivalent and be able to inject animals ip and iv. Independent use of the IVIS
Molecular biology: cloning using Gateway system
Flowcytometry and cell sorting
The candidate must hold a Master in Biology or Biochemistry.
We offer a position in a dynamic environment within modern and fully equipped facilities.

Vi tilbyr:

 

      We offer a position in a dynamic environment within modern and fully equipped facilities. 

 

How to apply:
Interested persons should submit the following documents to Webcruiter (note that applications lacking any of these three requirements will be discarded automatically, and only applications in Webcruiter will be evaluated):
A concise application letter (1 page)
A letter supporting command in the listed methods, eventually through publications/patents or visual proof (data)
Curriculum vitae
 
Questions about the position can be sent to the following e-mail addresses: sebastw@rr-research.no and jorrit.enserink@ibv.uio.no